Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in China, has renewed its partnership with Shanghai Healthcare Capital (SHC) and the Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences (CEMCS, CAS). The trio initially agreed to establish an innovative achievement incubation platform in September 2020, marking a significant step in the collaboration aimed at advancing pharmaceutical research and development.
Since the inception of the partnership, notable progress has been achieved in the field of antischizophrenia small molecule drugs. This collaboration combines the pharmaceutical expertise of Shanghai Pharmaceuticals with the financial acumen of SHC and the cutting-edge scientific research capabilities of CEMCS, CAS, to create a robust platform for incubating innovative pharmaceutical achievements.- Flcube.com
